Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...
rheumatologyadvisor21h
Treatment Persistence in Psoriasis Varies by the Biologic Therapy Used
Treatment persistence varied by biologic therapy use, sex, and diagnostic codes among patients with psoriasis.